Table 4. Baseline characteristics and response according by treatment group.
| Primary Rd until progression (n=9) | Primary Rd stopped before progression (n=11) | Primary Rd stopped with progression and restarted (n=5) | Rd induction followed by SCT (n=8) | |
|---|---|---|---|---|
| Age, years, median (range) | 65 (36–70) | 60 (40–78) | 55 (32–75) | 62 (36–73) |
| Prior plasma cell disorder, N | 6 (3 MGUS/SMM; 3 plasmacytoma) | 3 (3 MGUS/SMM) | 3 (2 MGUS/SMM; 1 plasmacytoma) | 3 (1 MGUS/SMM; 2 plasmacytoma) |
| MDE at presentation | Bone, 8 Anemia, 1 | Bone, 10 Anemia, 1 | Bone, 3 Anemia, 1 Hypercalcemia, 1 | Bone, 7 Anemia, 1 |
| Molecular classification, N | Trisomies, 5 t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1 | Trisomies, 6t(11;14), 1 Not done, 4 | Trisomies, 3 Normal/insufficient, 1 Not done, 1 | Trisomies, 4 Isolated del 13, 2 Normal/insufficient, 2 |
| Best response to therapy | CR, 7 VGPR, 2 | CR, 9 VGPR, 1 PR, 1 | CR, 2 VGPR, 2 PR, 1 | CR, 7 PR, 1 |
Abbreviations: CR, complete response; MDE, myeloma defining event; MGUS, monoclonal gammopathy of undetermined significance; Rd, lenalidomide–dexamethasone; SCT, stem cell transplantation; SMM, smoldering multiple myeloma.